FGFR2 and cholangiocarcinoma: In addition to non-selective tyrosine kinase inhibitors, which have shown activity in cholangiocarcinoma with FGFR2 fusion, a number of phase II trials have demonstrated efficacy for targeted FGFR inhibitors [12].